-+ 0.00%
-+ 0.00%
-+ 0.00%

Dermapharm Publishes Q3 2026 Results Call Transcript

PUBT·11/16/2026 12:26:09
Listen to the news
Dermapharm Publishes Q3 2026 Results Call Transcript
  • Dermapharm reaffirmed 2026 guidance at its November 12 third-quarter results webcast, expecting branded products to offset weakness elsewhere.
  • Attendees included Chief Financial Officer Christof Dreibholz, Chief Marketing Officer Andreas Eberhorn and Britta Hamberger.
  • Nine-month revenue rose 1.7% to 884 million; operating cash flow increased 10% to approximately 149 million.
  • Management acknowledged an organic decline in third-quarter branded pharmaceuticals revenue, citing likely timing effects pending further analysis.
  • Dreibholz expects BaFin to publish its decision shortly, with no material impact on financial position, operating results or guidance.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermapharm Holding SE published the original content used to generate this news brief on November 16, 2026, and is solely responsible for the information contained therein.